Phase II Trial of FavId™ (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed follicular B-cell non-Hodgkin's lymphoma (NHL)

- Grade 1, 2, or 3

- Progressive disease AND did not receive autologous immunoglobulin idiotype-KLH
conjugate vaccine (FavId™) while enrolled on protocol FAV-ID-06

- Meets 1 of the following criteria:

- Received salvage therapy after completion of protocol FAV-ID-06

- At least 4 weeks, but no more than 4 months, since prior salvage therapy

- Did not receive salvage therapy after completion of protocol FAV-ID-06

- At least 4 weeks, but no more than 4 months, since completion of prior
treatment on protocol FAV-ID-06

- No history of CNS lymphoma OR meningeal lymphomatosis

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Cardiovascular

- No history of congestive heart failure

Pulmonary

- No history of compromised pulmonary function

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- HIV negative

- No active bacterial, viral, or fungal infection

- No psychiatric disorder

- No other serious nonmalignant disease that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

- See Disease Characteristics

- No prior allogeneic transplantation*

- No prior rituximab regimen* other than that administered on protocol FAV-ID-06
(rituximab 375 mg/m^2 IV weekly for 4 weeks)

Chemotherapy

- No prior purine analogues* (e.g., fludarabine or cladribine)

Endocrine therapy

- No prior or concurrent steroids (e.g., steroid doses in excess of daily replacement)

Radiotherapy

- Not specified

Surgery

- Not specified

Other

- Recovered from prior salvage therapy

- No prior or concurrent immunosuppressive therapy

- No prior investigational agents*

- No other concurrent antilymphoma therapy NOTE: *As salvage therapy administered
between completion of protocol FAV-ID-06 and enrollment onto this study